Auflistung Nach Schlagwort "interleukin 23"
Anzeige der Dokumente 1-7 von 7
-
Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data
(2017)Psoriatic arthritis (PsA) is a psoriasis (Ps)-associated inflammatory joint disease that affects peripheral joints, entheses, spine, and eyes. PsA and Ps are likely to be the same disease. PsA develops in nearly 70% of ... -
IL-10 producing Bregs are impaired in psoriatic arthritis and psoriasis and inversely correlate with IL-17- and IFNγ-producing T cells
(2017)Our aim was to study CD19(+)CD27(+)CD24(high) memory and CD19(+)CD24(high)CD38(high) transitional and IL-10 + Breg cells, known to inhibit Th1 and Th17 cells in experimental arthritis, in psoriatic arthritis (PsA) and ... -
IL-35: a new immunomodulator in autoimmune rheumatic diseases
(2018)IL-35 is a relatively new cytokine that emerges as an important immunomodulator. IL-35 belongs to IL-12 cytokine family that includes IL-12, IL-23, IL-27, and IL-35. These cytokines are heterodimers that share subunits and ... -
Mini review: New treatments in psoriatic arthritis. Focus on the IL-23/17 Axis
(2019)Psoriasis, an inflammatory skin disease, and psoriatic arthritis (PsA), an inflammatory arthritis, share clinical, genetic, and pathogenic factors and may be summed as one disease, the psoriatic disease. Interleukin (IL)-17 ... -
Myeloid-derived suppressor cells in prostate cancer: Present knowledge and future perspectives
(2022)Several lines of research are being investigated to better understand mechanisms implicated in response or resistance to immune checkpoint blockade in prostate cancer (PCa). Myeloid-derived suppressor cells (MDSCs) have ... -
On the immunoregulatory role of statins in multiple sclerosis: the effects on Th17 cells
(2019)Statins, the cholesterol-lowering drugs, also possess immunomodulatory properties, affecting among others T cell activation and differentiation, antigen presentation, and regulatory T cell (Tregs) maintenance and ... -
Regulatory B and T lymphocytes in multiple sclerosis: friends or foes?
(2018)Current clinical experience with immunomodulatory agents and monoclonal antibodies in principle has established the benefit of depleting lymphocytic populations in relapsing–remitting multiple sclerosis (RRMS). B and T ...